Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.02. | Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright | 23 | Investing.com | ||
ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
19.02. | Arcus Biosciences stock target cut to $18 at H.C. Wainwright | 4 | Investing.com | ||
18.02. | Arcus Biosciences Shares Are Down Today: What's Going On? | 1 | Benzinga.com | ||
18.02. | Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market | 1 | RTTNews | ||
18.02. | Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry | 5 | Investing.com | ||
18.02. | Arcus Biosciences stock dips after pricing $150M offering | 1 | Seeking Alpha | ||
18.02. | Arcus Biosciences treibt Krebsmedikament Casdatifan nach Auslaufen des Gilead-Deals voran | 16 | Investing.com Deutsch | ||
18.02. | Arcus Biosciences sets $11/share for $150M stock offering | 1 | Investing.com | ||
18.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.01. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
07.11.24 | Arcus Biosciences GAAP EPS of -$1.00 beats by $0.04, revenue of $48M beats by $9.05M | 2 | Seeking Alpha | ||
06.11.24 | Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update | 181 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
06.11.24 | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
06.11.24 | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.11.24 | Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts | 1 | Benzinga.com | ||
24.10.24 | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
24.10.24 | Citi raises Arcus Biosciences target to $46, maintains buy | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 85,55 | 0,00 % | Bayer, BioNtech, Defence Therapeutics: Die neue Biotech-Realität eröffnet Chancen | Die Pharmabranche ist von den US-Zöllen ausgenommen. Doch wird für die Branche damit alles gut? Während der German Biotech Days in Heidelberg, die in der vergangenen Woche stattfanden, zeigten sich... ► Artikel lesen | |
CUREVAC | 2,766 | +0,36 % | Von abgerauscht bis stark gehalten - CureVac, Formycon, Vidac Pharma | Die Analysten in Deutschland sind bezüglich der Konjunkturerwartungen pessimistisch. Das ZEW-Barometer ist im April so deutlich gefallen, wie dies zuletzt im März 2022 der Fall war, nach dem Beginn... ► Artikel lesen | |
STRYKER | 306,10 | +0,39 % | Stryker Aktie: Leichte Erholung nach Talfahrt | Trotz Jahresverlust von 12% halten Experten an Kaufempfehlungen für den Medizintechnik-Konzern fest. Hohe Bewertungskennzahlen sorgen jedoch für Skepsis. Die Stryker-Aktie zeigt heute erste Anzeichen... ► Artikel lesen | |
INFLARX | 0,929 | -0,38 % | InflaRx Aktie: Was diese Woche zählt | Das Biotech-Unternehmen aus Jena verzeichnet trotz erheblicher Kursverluste im Jahresverlauf überraschend positive Analysteneinschätzungen mit hohen Kurszielen. Die InflaRx Aktie verzeichnete am vergangenen... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 88,90 | -0,31 % | What 16 Analyst Ratings Have To Say About Neurocrine Biosciences | ||
VAXART | 0,308 | +2,33 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 51,96 | -2,40 % | Halozyme Therapeutics, Inc.: European Commission Approved Subcutaneous DARZALEX (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility | Subcutaneous DARZALEX® is co-formulated with Halozyme's ENHANZE® drug delivery technology
SAN DIEGO, April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.... ► Artikel lesen | |
IMMATICS | 3,694 | -1,28 % | Immatics Announces Full Year 2024 Financial Results and Business Update | Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203... ► Artikel lesen | |
XOMA ROYALTY | 17,900 | +1,70 % | XOMA Royalty Corporation: XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements | Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder... ► Artikel lesen | |
MANNKIND | 3,968 | -0,48 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
BEIGENE LTD ADR | 202,00 | -0,98 % | BEIGENE (06160): DATE OF FIRST QUARTER 2025 FINANCIAL RESULTS ANNOUNCEMENT AND NOTICE OF AUDIT COMMITTEE ACTION | ||
AC IMMUNE | 1,316 | +0,46 % | AC Immune SA: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update | AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential... ► Artikel lesen | |
ESPERION | 0,868 | +4,03 % | ESPR: EU startet neuen Ökodesign-Plan für nachhaltige Produkte | ||
ROCKET PHARMACEUTICALS | 5,482 | -1,62 % | Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress | CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare... ► Artikel lesen | |
RECORDATI | 48,340 | -0,21 % | Recordati: RECORDATI: FDA GRANTS ISTURISA (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME | RECORDATI: FDA GRANTS ISTURISA®
(OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME
ISTURISA® is a cortisol synthesis inhibitor... ► Artikel lesen |